LDOS:NYSELeidos Holdings, Inc. Analysis
Data as of 2026-03-10 - not real-time
$173.39
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Leidos (LDOS) is trading at $173.38, just below its 20‑day SMA of 175.42 and well under the 50‑day SMA of 184.56, indicating short‑term pressure but still above the key support level of 161.05. The RSI of 44 suggests the stock is not yet oversold, while the MACD histogram is positive (+0.67), giving a modest bullish signal despite a neutral overall trend. Valuation metrics show a trailing PE of 15.6, far below the industry average of 36.9, yet the DCF‑derived fair value of $86.4 is less than half the market price, highlighting a divergence between market expectations and intrinsic estimates. The company delivers a modest dividend yield of 0.92% with a low payout ratio (14.6%), supporting dividend sustainability. High 30‑day volatility at 53.9% and decreasing volume point to elevated short‑term risk, but a low beta of 0.52 tempers market‑wide exposure. Strong fundamentals—ROE of 31%, positive free cash flow, and a solid backlog of defense contracts—provide a resilient earnings base. Analysts maintain a “buy” consensus with a mean target of $212.5, implying ~22% upside, while recent news highlights accelerated migration of Defense Agency workloads to DODNet and successful deployment of the Terminal Flight Data Manager system, underscoring growth catalysts. In summary, LDOS appears fairly valued with upside potential driven by defense and AI initiatives, but short‑term price pressure and high volatility warrant cautious positioning.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term SMA and decreasing volume
- Neutral trend with modest bullish MACD histogram
- High short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Analyst price targets implying ~22% upside
- Strong defense contract pipeline and AI initiatives
- Low PE relative to industry peers
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained ROE above 30% and positive free cash flow
- Dividend sustainability with low payout ratio
- Strategic position in government and commercial security markets
Key Metrics & Analysis
Financial Health
Revenue Growth-3.60%
Profit Margin8.43%
P/E Ratio15.6
ROE31.03%
ROA9.90%
Debt/Equity107.66
P/B Ratio4.5
Op. Cash Flow$1.8B
Free Cash Flow$1.1B
Industry P/E36.9
Technical Analysis
TrendNeutral
RSI44.0
Support$161.05
Resistance$196.00
MA 20$175.42
MA 50$184.56
MA 200$178.23
MACDBullish
VolumeDecreasing
Fear & Greed Index78.09
Valuation
Fair Value$86.42
Target Price$212.46
Upside/Downside22.54%
GradeFair
TypeBlend
Dividend Yield0.92%
Risk Assessment
Beta0.52
Volatility53.89%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.